A study to check the outcomes of Triple Negative Breast Cancer patients with the presence of Estrogen receptor Beta and TP53 mutation and the outcomes of adding the drug Tamoxifen in these patients.

Estrogen Receptor-Beta & TP53 Status as prognostic markers in Triple Negative Breast Cancer and their clinical outcomes with Tamoxifen(Selective Estrogen Receptor Modulator) - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/09/057359

Enrollment

100

Registered

2023-09-11

Start date

Unknown

Completion date

Unknown

Last updated

2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C509- Malignant neoplasm of breast of unspecified site

Interventions

Intervention1: TAMOXIFEN 20mg: The patients with Estrogen receptor beta positive and having TP53 mutation will be given Tab Tamoxifen 20mg OD for 5 years in addition to the standard treatment for Tri

Eligibility

Inclusion criteria

Inclusion criteria: 1)All triple negative breast cancer patients will be included 2)All stages of breast cancer patients will be included

Exclusion criteria

Exclusion criteria: 1)Luminal Breast Cancer patients 2)Pregnant females 3)Breastfeeding females 4)Patients receiving olaparib

Design outcomes

Primary

Measure	Time frame
Progression free survivalTimepoint: Between date of study entry and date of progression or death due to any cause for upto 24 months after therapy start	—

Secondary

Measure	Time frame
Overall survivalTimepoint: Between date of study entry and date of death due to any cause after therapy start	—

Countries

India

Contacts

Public ContactDr Wesley M Jose

Amrita Institute of Medical Sciences

wesleymjose@aims.amrita.edu7025759415

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026